Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
作者： Hua Shen , Fang Zhu , Jinyuan Liu , Tongpeng Xu , Dong Pei
DOI: 10.1371/JOURNAL.PONE.0103305
关键词:
摘要: … procedures in the First Affiliated Hospital of Nanjing Medical University, Jiangsu (China), … pathology department of First Affiliated Hospital of Nanjing Medical University, Jiangsu (China), …
harvard.edu
core.ac.uk 
sci-hub.se 参考文章(58)
Shinichi Toyooka, Katsuyuki Kiura, Tetsuya Mitsudomi, None, EGFR mutation and response of lung cancer to gefitinib. The New England Journal of Medicine. ,vol. 352, pp. 2136- ,(2005) , 10.1056/NEJM200505193522019
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Tomoyuki Araya, Kazuo Kasahara, Yoshiki Demura, Hiroki Matsuoka, Masaru Nishitsuji, Koichi Nishi, Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer Lung Cancer. ,vol. 80, pp. 344- 346 ,(2013) , 10.1016/J.LUNGCAN.2013.02.014
Bing Li, Shengxiang Ren, Xuefei Li, Yongsheng Wang, David Garfield, Songwen Zhou, Xiaoxia Chen, Chunxia Su, Mo Chen, Peng Kuang, Guanghui Gao, Yayi He, Lihong Fan, Ke Fei, Caicun Zhou, Gerald Schmit-Bindert, MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer. ,vol. 83, pp. 146- 153 ,(2014) , 10.1016/J.LUNGCAN.2013.11.003
Shen Hua, Xu Xiaotao, Guo Renhua, Yin Yongmei, Liu Lianke, Gao Wen, Shu Yongqian, None, Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells Biomedicine & Pharmacotherapy. ,vol. 66, pp. 89- 97 ,(2012) , 10.1016/J.BIOPHA.2011.09.013
YU HUANG, YU CHEN, QIN MEI, YUAN CHEN, SHIYING YU, SHU XIA, Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds Oncology Reports. ,vol. 29, pp. 2486- 2492 ,(2013) , 10.3892/OR.2013.2357
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
Fred R Hirsch, Samir Witta, Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer Current Opinion in Oncology. ,vol. 17, pp. 118- 122 ,(2005) , 10.1097/01.CCO.0000155059.39733.9D
HEE JOUNG KIM, SEO YOUNG OH, WAN SEOP KIM, SUN JONG KIM, GWANG HA YOO, WON DONG KIM, KYE YOUNG LEE, Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncology Letters. ,vol. 5, pp. 271- 276 ,(2013) , 10.3892/OL.2012.950
Shirish M. Gadgeel, Antoinette Wozniak, Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer Clinical Lung Cancer. ,vol. 14, pp. 322- 332 ,(2013) , 10.1016/J.CLLC.2012.12.001